76 related articles for article (PubMed ID: 9246222)
1. Effect of chronic pretreatment with the sigma ligand JO 1784 on CRF-induced changes in behaviour, neurotransmitter and immunological function in the rat.
Song C; Earley B; Leonard BE
Neuropsychobiology; 1997; 35(4):200-4. PubMed ID: 9246222
[TBL] [Abstract][Full Text] [Related]
2. Central neuropeptide Y and the sigma ligand, JO 1784, reverse corticotropin-releasing factor-induced inhibition of gastric acid secretion in rats.
Gué M; Yoneda M; Mönnikes H; Junien JL; Taché Y
Br J Pharmacol; 1992 Nov; 107(3):642-7. PubMed ID: 1472962
[TBL] [Abstract][Full Text] [Related]
3. Central action of sigma receptor ligand, JO 1784, to suppress CRF-induced inhibition of gastric function in conscious rats.
Yoneda M; Junien JL; Taché Y
Eur J Pharmacol; 1992 Nov; 223(2-3):197-9. PubMed ID: 1478267
[TBL] [Abstract][Full Text] [Related]
4. Reversal of CRF- and dopamine-induced stimulation of colonic motility by CCK and igmesine (JO 1784) in the rat.
Gué M; Gleïzes-Escala C; Del Rio-Lacheze C; Junien JL; Buéno L
Br J Pharmacol; 1994 Mar; 111(3):930-4. PubMed ID: 7912631
[TBL] [Abstract][Full Text] [Related]
5. The sigma ligand JO 1784 prevents trimethyltin-induced behavioural and sigma-receptor dysfunction in the rat.
O'Connell AW; Earley B; Leonard BE
Pharmacol Toxicol; 1996 May; 78(5):296-302. PubMed ID: 8737963
[TBL] [Abstract][Full Text] [Related]
6. Behavioral, neurochemical, and immunological responses to CRF administration. Is CRF a mediator of stress?
Song C; Earley B; Leonard BE
Ann N Y Acad Sci; 1995 Dec; 771():55-72. PubMed ID: 8597429
[TBL] [Abstract][Full Text] [Related]
7. Neuropeptide Y and sigma ligand (JO 1784) act through a Gi protein to block the psychological stress and corticotropin-releasing factor-induced colonic motor activation in rats.
Junien JL; Gue M; Bueno L
Neuropharmacology; 1991 Oct; 30(10):1119-24. PubMed ID: 1661865
[TBL] [Abstract][Full Text] [Related]
8. Comparison between the effects of sigma receptor ligand JO 1784 and neuropeptide Y on immune functions.
Song C; Leonard BE
Eur J Pharmacol; 1998 Mar; 345(1):79-87. PubMed ID: 9593598
[TBL] [Abstract][Full Text] [Related]
9. Evidence for an anti-amnesic effect of JO 1784 in the rat: a potent and selective ligand for the sigma receptor.
Earley B; Burke M; Leonard BE; Gouret CJ; Junien JL
Brain Res; 1991 Apr; 546(2):282-6. PubMed ID: 1676927
[TBL] [Abstract][Full Text] [Related]
10. Neuropeptide Y and sigma ligand (JO 1784) suppress stress-induced colonic motor disturbances in rats through sigma and cholecystokinin receptors.
Gue M; Junien JL; Del Rio C; Bueno L
J Pharmacol Exp Ther; 1992 Jun; 261(3):850-5. PubMed ID: 1318376
[TBL] [Abstract][Full Text] [Related]
11. Beneficial effects of sigma agonists on the age-related learning impairment in the senescence-accelerated mouse (SAM).
Maurice T; Roman FJ; Su TP; Privat A
Brain Res; 1996 Sep; 733(2):219-30. PubMed ID: 8891305
[TBL] [Abstract][Full Text] [Related]
12. Attenuation by a sigma1 (sigma1) receptor agonist of the learning and memory deficits induced by a prenatal restraint stress in juvenile rats.
Meunier J; Gué M; Récasens M; Maurice T
Br J Pharmacol; 2004 Jun; 142(4):689-700. PubMed ID: 15205309
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-2-induced changes in behavioural, neurotransmitter, and immunological parameters in the olfactory bulbectomized rat.
Song C; Leonard BE
Neuroimmunomodulation; 1995; 2(5):263-73. PubMed ID: 8739199
[TBL] [Abstract][Full Text] [Related]
14. The behavioural and electrophysiological effects of CRF in rat frontal cortex.
Zieba B; Grzegorzewska M; Brański P; Domin H; Wierońska JM; Hess G; Smiałowska M
Neuropeptides; 2008; 42(5-6):513-23. PubMed ID: 18617263
[TBL] [Abstract][Full Text] [Related]
15. The sigma receptor ligand JO 1784 (igmesine hydrochloride) is neuroprotective in the gerbil model of global cerebral ischaemia.
O'Neill M; Caldwell M; Earley B; Canney M; O'Halloran A; Kelly J; Leonard BE; Junien JL
Eur J Pharmacol; 1995 Sep; 283(1-3):217-25. PubMed ID: 7498313
[TBL] [Abstract][Full Text] [Related]
16. Differential monoaminergic, neuroendocrine and behavioural responses after central administration of corticotropin-releasing factor receptor type 1 and type 2 agonists.
de Groote L; Peñalva RG; Flachskamm C; Reul JM; Linthorst AC
J Neurochem; 2005 Jul; 94(1):45-56. PubMed ID: 15953348
[TBL] [Abstract][Full Text] [Related]
17. Dorsomedial hypothalamus CRF type 1 receptors selectively modulate inhibitory avoidance responses in the elevated T-maze.
Silva MS; Pereira BA; Céspedes IC; Nascimento JO; Bittencourt JC; Viana MB
Behav Brain Res; 2014 Sep; 271():249-57. PubMed ID: 24937051
[TBL] [Abstract][Full Text] [Related]
18. Corticotropin-releasing factor induces differential behavioral and cardiovascular effects after intracerebroventricular and lateral hypothalamic/perifornical injections in rats.
Diamant M; Kashtanov SI; Fodor M; de Wied D
Neuroendocrinology; 1992 Nov; 56(5):750-60. PubMed ID: 1488107
[TBL] [Abstract][Full Text] [Related]
19. Cholecystokinin tetrapeptide effects on HPA axis function and elevated plus maze behaviour in maternally separated and handled rats.
Greisen MH; Bolwig TG; Wörtwein G
Behav Brain Res; 2005 Jun; 161(2):204-12. PubMed ID: 15922046
[TBL] [Abstract][Full Text] [Related]
20. Repeated administration of Sigma ligands alters the population activity of rat midbrain dopaminergic neurons.
Zhang J; Chiodo LA; Wettstein JG; Junien JL; Freeman AS
Synapse; 1993 Mar; 13(3):223-30. PubMed ID: 8497808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
